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CXCR4 chemokine receptor monoclonal antibody was found to reduce the level of lung metastasis by 61-68 percent. Based on these findings supporting the role for chemokine ligand-receptor interactions in promoting metastasis of breast cancer, we develop small molecule antagonists to CXCR4. This was accomplished by screening in a competitive assay synthetic combinatorial libraries (SCLs) made up of D-amino acid peptides for their ability to antagonize CXCR4 receptor function using HeLa cells and PBMC cells (used as standard), and breast cancer cells (MDA-MB-231 and DU4475, known to express CXCR4), and a monoclonal antibody anti-CXCR4 known to block chernotaxis induced by CXCL12 (formerly known as SDF1-j_). The SCL approach, particularly when generated in a positional scanning (PS) format, allows the direct identification of the key residue(s) of active peptide sequence(s) from the library screening. Following the screening of a library, candidate sequences were synthesized and their inhibitory activity on the binding of anti-CXCR4 antibody was evaluated as well as their ability to abrogate the migratory response of cells induced by SDF-I_.
14. SUBJECT 
INTRODUCTION
Breast cancer cells were recently reported to express functionally active chemokines that may promote metastasis (1). Specifically, chemokines (e.g., SDF-la) and their receptors (e.g., CCR7 and CXCR4) are now believed to play a critical role in motility, homing, and proliferation of cancer cells at specific metastatic sites. For instance, the signaling pathways activated upon interaction of CXCR4 with SI)F-la play a role in the survival and proliferation of cancer cells once they are localized in a specific organ. These in vitro and in vivo inhibition studies make CXCR4 a potential target for preventing the conversion of premalignant to invasive breast cancer. The overall aim of this proposal was therefore to develop small molecule chemokine antagonists that can be used as simple model systems to further understand the role of chemokine ligand-receptor interactions in breast cancer evolution, as well as lead compounds for potential treatment against metastatic breast tumors. This was accomplished by using a synthetic combinatorial library (SCL) approach to identify D-amino acid hexa-and decapeptides that block the anti-CXCR4 antibody binding to CXCR4-expressing cells. D-peptides, by their nature, are much more stable to proteolysis and immune clearance and are attractive alternate drug candidates to natural L-peptides.
RESEARCH ACCOMPLISHMENTS

Task 1: To determine the experimental conditions for an optimal detection of CXCR4 expression by flow cytometry
The detection of CXCR4 recognition by Cy-chrome labeled anti-CXCR4 mAb 12G5 (Pharmingen, San Diego, CA) was evaluated by flow cytometry for two breast cancer cell lines, MI)A-MB-231, known to express CXCR4 (2) and MDA-MB-468, a CXCR4-deficient cell line (1) used as negative control, as well as for He-La cell line and peripheral blood mononuclear cells (PBMCs) from healthy volunteers, used as positive controls. The corresponding isotype IgG2a was used as a negative control to subtract nonspecific binding. A 30 min incubation at room temperature of 2xl.0 6 cells with 5 l.tl mAb resulted in 8% and 4% specific recognition for MI)A-MB-231 and MI)A-MB-468 cells, respectively, and 80 to 85% specific recognition for HeLa and PBMCs. The low recognition of the MDA cells observed in our flow cytometry measurements agrees with a recent finding reported by Helbig et al. (3) that less than 10% of MI)A-MB-231 cells grown in culture express CXCR4 on their surface. A prerequisite to identify individual active compounds from mixture-based combinatorial libraries is a significant signal to noise ratio. Due to the low expression of CXCR4 on MDA cells, we selected to use PBMCs as standard cells to develop CXCR4 antagonists from libraries and evaluate the antagonistic activity of the best candidates with breast cancer cells.
Task 2: To screen two peptide synthetic combinatorial libraries fir their ability to antagonize CXCR4 receptor function
The libraries used in these studies are mixture-based SCI~s and represent collections of peptides that are screened as mixtures of soluble compounds [i.e., not attached to solid supports (4)]. They were generated in a positional scanning (PS) format, which allows the determination of key residues at all Table 1 . Hexapeptide PS-SCL description diversity positions in a single screening assay (5).
• amino acid hexapeptide library. Each graph represents the inhibitory activity of a position represent the given sublibrary. Each bar represents the percent inhibition of a mixture defined same active peptide(s) with the amino acid listed on the x-axis at 100 pig/ml. The horizontal line represents present in the the average percent inhibition plus 1.5 standard deviation value for all mixtures corresponding present in a given sublibrary and is used to differentiate those mixtures having mixtures, then significant activity relative to the others. The hollow bars represent the mixtures that combinations of these were selected to carry out the deconvolution process.
residues lead to active d o Ig h i k I r possible hexapeptide sequences having an alanine at position 1, and mixture number 120 was defined with tyrosine at position 6 (Ac.-xxxxxy-.NH 2 ), i.e., contains all possible hexapeptide sequences having a tyrosine at position 6. Therefore, each individual hexapeptide was present in 6 separate mixtures, each one differing from the position of the fixed amino acid. All 120 mixtures were mixed with PBMCs and the recognition of cellsurface coreceptors by a monoclonal antibody specific for CXCR4 was monitored by FACS as follows. 6x10 5 cells/ml PB3MCs that were pre-activated with human recombinant IL-2 (Pharmingen, San Diego, CA) for 8-12 days were incubated with peptide mixtures for 30 min at 37'C under 5% C02 atmosphere in FACS solution (PBS, 0.1%13SA, 0.1% Na azide) followed by a 30 min incubation at room temperature with 10[d1 of anti-CXCR4 mAb 12G5. The corresponding isotype IgG2a was used in all experiments. The cells were washed with 2 ml of FACS solution, resuspended in 0.5 ml of FACS solution, and analyzed using a FACScallibur (Becton Dickinson). The specific fluorescence corresponding to the cell surface molecule was calculated as median of all positive events subtracting the fluorescence of the isotype control.
As shown in Figure 1 , a limited number of mixtures exhibited antagonistic activity, indicating the presence of a limited number of active sequences within the library. The next step following the screening of a PS-SCL is to synthesize all sequences corresponding to all possible combinations of the amino acids defining the most active mixtures from each sublibrary. We selected mnixtures that inhibit CXCR4 recognition at a percentage above the average plus 1.5 standard deviation value within each sublibrary in a 6 manner that the amino acids defining those mixtures were of different chemical character (hollow bars in Fig. 1) . For example, only one of the two mixtures defined with tyrosine or tryptophan were selected at positions 1, 4, 5, and 6. This lead to the generation of 36 individual pcptidcs (2xlxlx2x3x3 = 36). In addition, a number of arginine/tyrosine L-and D-amino acid hexapeptides that were generated for an unrelated study were selected for further evaluation as described below. Similarly to known CXCR4 antagonists, the i)-hexapcptides to bc synthesized and/or tested have a cationic charactcr. The site of recognition in the extracellular domain of CXCR4 that can be blocked with the mAb 12(G5 includes an anionic region (6) , which could interact with cationic peptides. Since the 9-mer poly--D-arginine ALX 40-4C (7) and 1O-mer D-peptides derived from SDF-I a (8) were shown to inhibit HIV-I entry by targeting CXCR4, we also initiated the screening of a 1)-amino acid decapeptide PS-SCL. This library was built in a manner similar to the hexapeptide library described above (Ac-oxxxxxxxxx-NH 2 to Ac-xxxxxxxxxo-NH 2 ) and consisted of 200 separate mixtures arranged in 10 sublibraries. Each mixture contained 3.2 x 10'" (199) different peptides in approximately equimolar concentration, and the entire decamer library contained a total of 6.5 x 10" (20 x 199) different individual decapeptides. Three sublibraries were tested so far in a manner similar to the hexapeptide SCL (Fig. 2) .
As for the hexapeptide library, the most active mixtures are mostly defined with basic residues (arginine or lysine) or tyrosine. While the screening of the library will be completed in the near future, a number of arginine/tyrosine D-amino acid decapeptides that were generated for an unrelated study were selected for further evaluation as described below.
Task 3:
To synthesize candidate peptide sequences All individual peptides were synthesized by simultaneous solidphase technology using standard tBoc chemistry and p-methylbenzydrylamine resin (0.81meq/g, 100-200 mesh), which was contained within a sealed polypropylene mesh packet (9) . Final cleavage and deprotection steps were carried out with liquid hydrogen fluoride (HF) using a "low-high" HF cleavage protocol (10, 11) . The identity and purity of the peptides were analyzed by mass spectral analysis interfaced with a liquid chromatography system (Finnigan LCQ) and analytical reversed phase high performance liquid chromatography (RP tPI,C) using a Beckman System Gold HPILC. The peptides were purified by preparative RP HPLC using a Waters Milliprep 300 preparative HPLC with a Foxy fraction collector.
Task 4: To determine the antagonistic activity of the candidate peptides
In a first experiment, the 36 1)-amino Table 2 . Active hcxapcptidcs toward PBMCs acid hexapeptides derived from the library were % Inhibition at 1,000nng/mi 100ng/ml long/ml assayed for inhibition of CXCR4 recognition Ac-R R W W R H1 -NH, 81% 65% 18%
using PBMCs by flow cytometry. As shown in Ac-R R W W C H1 -NHw 76% 16%
-- Figure 3 , the most active peptides exhibit 65 to Ac-r r w w c r -NH 2 75% 12%
--83% CXCR4 recognition at I[tg/ml.
62%
19%
In parallel, 14 L-or D-amino acid
hexapeptides derived from unrelated studies were Ac-R R W W R F -Ntt2 53% 37% - -----------------------------------------------. . similarly tested. The most active peptidcs are listed in Table 2 . The most active L-amino acid hexapeptidcs inhibited CXCR4 recognition with an ECjo value of 37 ng/ml.
Similarly, a set of 1)-amino acid decapeptides were assayed for inhibition of CXCR4 recognition. The most active peptide (D13-rr) exhibited antagonistic activity with EC5 0 at 29 nM levels (Fig. 4) . D O-rr and DI 6-rr were similarly effective while D5-rr exhibited a 10-fold lower activity (EC 50 values of 233 nM - Fig. 4) . 35 Ac-y h r y yr -NH 2 90% 29
Ac-y h r y r r -N1-1 2 88% 16
Ac-r h r y y h -NH 2 81% 15
Ac-r h r y sw -N11 2 81% 21
Ac-y h r w r w -NH 2 78%
3 Ac-r h r w r w -NH2 77% 5
Ac-r h r w sr -NH 2 77% 2 Ac-r h r w r r -NH2 77%
An alternative assay to flow cytometry was investigated to determine whether the identified peptides inhibit CXCR4 recognition by mAb 12G5. An ELISA assay was set up in which the peptides were preincubated with the cells overnight at 4°C, followed by 1 hr incubation at 37'C with mAb 12G5 and the inhibition was detected using europium-labeled streptavidin. As a positive control, HeLa cells were first used to ensure detection of antagonistic activities. In this assay, i16-rr inhibited CXCR4 recognition in HeLa cells with ECMo at 1.5 1 iM levels, i.e., 10--fold lower than the natural ligand SDF-la, while D)10-rr had a lower inhibitory effect than SDF-lh (Fig. 5) . Using the same experimental conditions (25,000 cells per well), a slight inhibition of CXCR4 recognition by mAb 12G5 could also been observed for D13-rr when testing MDA-MB-231 cells (Fig. 5) . Optimization studies are on going to determine the experimental conditions leading to an increased detection level of inhibition. pg/ml, a numbcr of peptides had a significant cffect confirming the antagonistic activity observed earlier (Fig. 6) . 1.3nM SDF-la (Fig. 8 ).
L-RR
Ac-FRWWRRfl-NH 2 The hexapeptide # 21 exhibit the greatest inhibitory effect with complete inhibition at the lowest concentration tested (0.96 ttM).
KEY RESEARCH ACCOMPLISHMENTS
Identify novel short peptides that block the recognition of CXCR4 by anti-CXCR4 mAb 12G5. CONCLUSION Using a combinatorial library approach, we have identified cationic D-amino acid hexapeptides and decapeptides that block the anti-CXCR4 antibody binding to CXCR4-expressing cells. The unique nature of these D-peptide inhibitors (i.e., length and nature of their sequences), as well as the importance of CXCR4 on breast cancer metastasis make these peptides useful tools to further explore the elements responsible for their inhibitory activity in a structure-activity relationship (SAR) study. Such study would provide important information on how small peptides may affect SDF-la binding to CXCR4, and further our understanding on the role of SDF-I a/CXCR4 interactions in the spread of breast cancer cells.
